GSK's Arexvy RSV Vaccine Gets Expanded Japan Approval for At-Risk Adults 18-59
GSK sits 40% above its 52-week low of $35.45.
Summary
GSK's RSV vaccine, Arexvy, has received expanded approval from Japan's MHLW to include adults aged 18-59 at increased risk for RSV disease, and explicitly includes immunocompromised patients.
Key Events · Product Development and Regulatory · GSK
-
Expanded Approval in Japan
Japan's Ministry of Health, Labour and Welfare (MHLW) has expanded the eligible population for Arexvy to include adults aged 18-49 years at increased risk for RSV disease.
-
Inclusion of Immunocompromised Patients
The prescribing information for Arexvy has been updated to explicitly include immunocompromised patients as an increased risk group.
-
Broader Market Access
Arexvy is now approved in Japan for adults aged 18-59 at increased risk and all adults 60 years and older, expanding its market reach.
Analysis · GSK · Life Sciences
This expanded approval significantly broadens the addressable market for GSK's key RSV vaccine, Arexvy, in Japan. By including adults aged 18-59 with increased risk and explicitly immunocompromised patients, GSK can reach a larger population vulnerable to severe RSV outcomes, potentially boosting sales and reinforcing Arexvy's market position. This follows a trend of positive regulatory developments for GSK's pipeline.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $49.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $99B. The 52-week trading range was $35.45 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.